The impact of iron overload in patients with acute leukemia and myelodysplastic syndrome on hepatic and endocrine functions

Mohamed A Yassin¹, Ashraf Soliman², Vincenzo De Sanctis³, Saloua M Hmissi⁴, Mohammad AJ Abdulla⁵, Yeslem Ekeibed², Omer Ismail², Abdulqadir Nashwan¹, Dina Soliman⁵, Mohammed Almusharaf⁶, Redwa Hussein⁶

¹ Hematology Section Medical Oncology NCCCR, Hamad Medical Corporation (HMC) Doha, Qatar; ² Department of Pediatrics, Hamad Medical Corporation (HMC), Doha, Qatar; ³ Pediatric and Adolescent Outpatient Clinic, Quisisana Hospital, Ferrara, Italy; ⁴ Blood Bank, Hamad Medical Corporation (HMC), Doha, Qatar; ⁵ Department of Laboratory Medicine and Pathology, National Center for Cancer Care and Research, Hamad Medical Corporation (HMC) Doha, Qatar; ⁶ Department of Pharmacy NCCCR, Hamad Medical Corporation (HMC) Doha, Qatar

Summary. Patients with hematologic malignancies undergoing chemotherapy and requiring blood transfusion usually have an elevated serum ferritin. These findings have led to the suggestion that iron overload is common and may have deleterious effects in these patients. However, the relationship between serum ferritin and parenchymal iron overload in such patients is unknown. Therefore, we measured the liver iron content (LIC) by the FerriScan® method and investigated the liver function and some endocrine tests in 27 patients with acute leukemia (AL) or myelodysplastic syndromes (MDS). Using FerriScan® method, the normal mean LIC levels are: 4.3±2.9 mg Fe/g dry weight (d.w.). In our patients, the mean serum ferritin level was 1965±2428 ng/mL. In our patients, the mean total iron in the blood received by them was 7177±5009 mg. In 6 out of 27 patients LIC was >7 mg Fe/g d.w. and in 11/27 serum ferritin was >1000 ng/ml. Measuring fasting blood glucose revealed 3/27 with diabetes mellitus and 4/27 with impaired fasting glucose (IFG). All patients had normal serum concentrations of calcium, parathormone (PTH), free thyroxine (FT4) and thyrotropin (TSH). Four patients had elevated serum alanine transferase (ALT). LIC was correlated significantly with ferritin level (r=0.5666; P<0.001) and the cumulative amount of iron in the transfused blood (r=0.523; P<0.001). LIC was correlated significantly with ALT (r=0.277; P=0.04) and fasting blood glucose (FBG) was correlated significantly with the amount of iron transfused (r=0.52, p<0.01) and ALT level (r=0.44; P<0.01). The age of patients did not correlate with LIC, FBG or ALT. In conclusions, these results contribute to our understanding of the prevalence of dysglycemia and hepatic dysfunction in relation to parenchymal iron overload in patients with hematologic malignancies undergoing chemotherapy and requiring blood transfusions. (www.actabiomedica.it)

Key words: acute leukemia, myelodysplastic disorders, liver iron content (LIC), Ferriscan®, serum ferritin, alanine transferase

Introduction

Iron overload is common in patients with hematologic malignancies requiring repeated blood transfusions and may have a deleterious effect on the outcome of these patients. These findings have led to the suggestion that iron overload is common and may have deleterious effects in these patients. Nevertheless, we
have little understanding of the distribution of iron in these patients and its possible effects on hepatic and endocrine functions.

Although liver biopsy is the most accurate method to diagnose liver pathology and iron content of the liver it is inconvenient and has potential complications. This approach can be replaced using magnetic resonance imaging (MRI) techniques. A standardized and validated MRI method is now registered in Europe and the United States (FerriScan®), with reproducible relationship between the value (R2) obtained by MRI and liver iron content (LIC) assessed by biopsy. This is potentially available in any hospital with an MRI scanner and with minimal training of local staff (1, 2).

We conducted this study in patients with myelodysplastic syndromes (MDS) or acute leukemia using hepatic FerriScan® method for the estimation of parenchymal iron overload prevalence and to clarify the relationship, if any, between iron burden, serum ferritin, liver enzymes and some endocrine functions.

**Patients and methods**

27 adult patients with acute myelogenous (AML) or lymphoblastic (ALL) leukemia (n=20) and MDS (n=7) were studied during their remission phase. We evaluated, in these groups of patients, using a cross-sectional study their serum ferritin levels, liver functions test, LIC and some endocrine functions. Both groups of patients were not receiving, before the study, iron chelation therapy. Lab. investigation, using standard commercial methods, included the measurement of fasting serum concentration of free thyroxine (FT4), thyrotropin (TSH), calcium, phosphate, parathormone (PTH, intact molecule). Fasting blood glucose and liver enzymes [serum aspartate aminotransferase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP)] were also determined.

Liver iron content was measured using the FerriScan® R2-MRI method (1-3). The method uses seven T2-weighted single spin-echo free-breathing sequences under fixed gain control with constant TR and increasing TE spaced at 1-3 ms intervals. The severity of liver iron overload was graded as following: LIC (severe) >15 mg Fe/g dry weight (d.w.), (moderate) 8-14.9 mg Fe/g d.w., and (mild) <8 mg Fe/g d.w. (1-3).

**Definition of endocrinopathy categories**

1. Evidence for diabetes mellitus: fasting glucose >6.9 mmol/l, and/or non-fasting glucose >11.1 mmol/l and/or exogenous insulin administration and/or use of oral hypoglycemic medications.

2. Evidence for primary hypothyroidism (low FT4, high TSH) or ongoing thyroid hormone replacement therapy.

Student “t test” was used to compare the laboratory data among the different groups when the data was normally distributed and Wilcoxon rank test when the data were not normally distributed. Linear regression equation was used to study possible correlations between different variables.

Institutional review board (IRB) approval was obtained from the HMC Research Center of Doha (Qatar) to perform the study.

**Results**

Lab investigations of 27 adult patients with acute and chronic leukemia who received chemotherapy and repeated blood transfusion showed that their mean serum ferritin was 1,965±2,428 ng/mL. Their mean total iron, received with blood transfusions, was 7,177±5,009 mg.

Diabetes mellitus, using the criteria of American Diabetes Association, was present in 3 out of 27 patients and impaired fasting glucose (IFG) in 4 out of 27 patients. All patients had normal serum concentrations of calcium, PTH, FT4 and TSH. Four patients had elevated ALT. LIC was correlated significantly with serum ferritin level (r=0.567, P<0.001) and the cumulative amount of iron received with blood transfusions (r=0.523, p<0.001). 11 out of 27 patients (40.7%) had a serum ferritin >1000 ng/ml. Using the FerriScan® method, the mean LIC was 4.3±2.9 mg Fe/g d.w. However, 6 out of 27 patients (22.2%) had a LIC >7 mg Fe/g d.w.

Comparison between acute and chronic cases showed that patients with acute leukemia had higher
serum ferritin concentrations and higher LIC compared to patients with chronic leukemia (Table 1).

LIC was correlated significantly with serum ferritin concentrations, ALT (r=0.277; P=0.04) and the amount of iron received with blood transfusions (Figure 1). FBG level was correlated significantly with the amount of iron transfused (r=0.52; P<0.01) and with ALT level (r=0.44; P<0.01). The age of patients did not correlate with LIC, FBG or ALT (Table 2).

Discussion

The accurate measurement of LIC is critical for the management of transfusional iron burden among patients receiving chronic transfusion therapy.

In this study, we report a high prevalence of hepatic iron overload, measured by FerriScan®, in patients with AML, ALL, or MDS. Although this is an indirect measurement, there was a strong correlation between liver T2* values and LIC measured by liver biopsy (1,3).

Table 1. Comparison between patients with acute versus chronic leukemia

|          | BMI | gender | Age | LIC | TSH | FT4 | Ferritin | Transfused Fe | AST | ALT | ALP | Glucose (F) |
|----------|-----|--------|-----|-----|-----|-----|----------|---------------|-----|-----|-----|------------|
| Chronic Leukemias |     |        |     |     |     |     |          |               |     |     |     |            |
| Mean     | 29.54 | M     | 48.86 | 3.00 | 1.56 | 13.28 | 1026.00  | 3066.00      | 19.71 | 26.00 | 90.14 | 6.20       |
| SD       | 5.05  | F     | 14.68 | 2.97 | 0.64 | 1.46  | 1402.21  | 2154.00      | 7.91  | 21.25 | 33.84 | 1.52       |
| Acute Leukemias |     |        |     |     |     |     |          |               |     |     |     |            |
| Mean     | 24.70 | M     | 15.43 | 4.38 | 1.50 | 13.42 | 2731.00  | 9352.00      | 31.00 | 40.43 | 111.57 | 7.21       |
| SD       | 4.41  | F     | 15.43 | 2.37 | 0.65 | 2.65  | 2200.00  | 4727.00      | 24.62 | 32.74 | 62.38 | 5.01       |

Abbreviations: aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP); #: p<0.05

Table 2. Regression analysis of different variables

|          | Age | BMI | gender | TSH | FT4 | Ferritin | Units bld | Transfused iron mg | PTH | BMI | AST | ALP | Glucose (F) |
|----------|-----|-----|--------|-----|-----|----------|-----------|------------------|-----|-----|-----|-----|------------|
| Age      | 1.00 |     |        |     |     |          |           |                  |     |     |     |     |            |
| LIC      | -0.09 | 1.00 |        |     |     |          |           |                  |     |     |     |     |            |
| TSH      | 0.11 |     |        | 0.25 | -0.13 | 1.00   |           |                  |     |     |     |     |            |
| FT4      | 0.03 | -0.55 |     | 0.42 | 0.29 | 1.00     |           |                  |     |     |     |     |            |
| Ferritin | -0.32 | 0.58 | -0.03 |     | 0.13 | 0.46     | 1.00      |                  |     |     |     |     |            |
| Units bld| -0.10 | 0.47 |     | 0.03 | 0.13 | 0.46     | 1.00      |                  |     |     |     |     |            |
| transfused iron mg | -0.10 | 0.47 |     | 0.03 | 0.13 | 0.46     | 1.00      |                  |     |     |     |     |            |
| PTH      | -0.07 | 0.00 | 0.43 | -0.29 | -0.48 | 0.475 | 1.00      |                  |     |     |     |     |            |
| BMI      | 0.56 |     |        | 0.42 | -0.27 | -0.30 | -0.30     | 0.58           | 1.00 |     |     |     |            |
| ALT      | -0.17 | 0.01 | -0.45 | 0.34 | 0.17 | 0.09 | 0.09      | 0.14           | 1.00 |     |     |     |            |
| ALP      | -0.18 | 0.28 | -0.36 | 0.30 | 0.71 | 0.08 | 0.08      | 0.26           | 1.00 |     |     |     |            |
| Glucose (F) | 0.21 |     |        | 0.25 | -0.10 | 0.15 | 0.21     | 0.52           | 0.52 |     |     |     |            |

Abbreviations: aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP); gluucose (F): fasting; #: p<0.05
Although hepatic involvement in acute leukemia is usually mild and silent at the time of diagnosis, leukemic infiltration in both portal tracts and sinusoids occurs frequently, and massive leukemic cell infiltration of the liver may present as fulminant hepatic failure (4).

In addition, drug-induced liver injury, bacterial or fungal infections can negatively affect the liver functions. In our patients with leukemia, 4 out of 27 had elevated ALT levels associated with high serum ferritin and LIC. A positive correlation was found between the amount of iron received through blood transfusions, LIC and ALT levels. In brief, these data suggest a deleterious effect of hepatic iron overload on its function (5, 6).

Hepatic iron overload has been associated with glucose dysregulation (7, 8). This deleterious effect can be mediated through three key mechanisms: 1) insulin deficiency, 2) insulin resistance, and 3) hepatic dysfunction (9-11). In support of this concept, we found a significant correlation between LIC and FBG concentration and ALT levels in our patients with malignancy.

The role of iron in the pathogenesis of diabetes is suggested by the increased incidence of type 2 diabetes in diverse causes of iron overload (12-15) and by the reversal or improvement of glucose homeostasis after reduction of iron load achieved with phlebotomy or iron chelation therapy (15, 16).

One study suggested that an optimal threshold for starting iron chelation therapy in these patients is 2,500 ng/mL. This recommendation was based on the observed relationship between LIC and serum ferritin levels, that correspond roughly to an LIC value of 5 mg Fe/g d.w. However, a lower threshold of serum ferritin and a LIC may be adopted in these patients due to the presence other associated co-morbidities (17).

In conclusion, patients with AL or MDS undergoing chemotherapy and repeated blood transfusions are at higher risk of increased parenchymal iron overload, hepatic dysfunction and dysglycemia. This can markedly increase their morbidity. It is suggested that oral chelation therapy based on evaluation of serum ferritin >1000 ng/ml or LIC >5 mg Fe/g d.w. can significantly decrease these morbidities.

References

1. St Pierre TG, Clark PR, Chua-Anusorn W, Fleming AJ, Jeffrey GP, Olynik JK, Pootrakul P, Robins E, Lindeman R. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105: 855-861.

2. Hankins JS, Mc Carville MB, Loeffler RB, Smeltzer MP, Onciu M, Hoffer FA, Li CS, Wang WC, Ware RE, Hillenbrand CM. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood 2009; 113: 4853-4855.

3. St Pierre TG, Clark PR, Chua-Anusorn W. Measurement and mapping of liver iron concentrations using magnetic resonance imaging. Ann N Y Acad Sci 2005; 1054: 379-385.

4. Litten JB, Rodriguez MM, Maniaci V. Acute lymphoblastic leukemia presenting in fulminant hepatic failure. Pediatr Blood Cancer 2006; 47: 842-845.

5. Thiele DL. Hepatic manifestations of systemic disease and other disorders of the liver. In: Sleisenger & Fordtran’s Gastrointestinal and Liver Disease. M Feldman, LS Friedman and M H Sleisenger Eds. Elsevier Science, Philadelphia, Pa, USA, 7th Edition, 2002, p. 1603.

6. Wilputte JY, Martinet JP, Nguyen P, Damoiseaux P, Rahier J, Geubel A. Chronic lymphocytic leukemia with portal hypertension and without liver involvement: a case report underlining the roles of increased spleno-portal blood flow and “protective” sinusoidal vasoconstriction. Acta Gastroenterol Belg 2003; 66: 303-306.

7. Hatunic M, Finucane FM, Brennan AM, Norris S, Pacini G, Nolan JJ. Effect of iron overload on glucose metabolism
in patients with hereditary hemochromatosis. Metabolism 2010; 59: 380-384.
8. Noetzli LJ, Mittelman SD, Watanabe RM, Coates TD, Wood JC. Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol 2012; 87: 155-160.
9. Swaminathan S, Fonseca VA, Alam MG, Shah SV. The role of iron in diabetes and its complications. Diabetes Care 2007; 30: 1926-3193.
10. De Sanctis V, Soliman AT, Elsedfy H, Pepe A, Kattamis C, El Kholy M, Yassin M. Diabetes and Glucose Metabolism in Thalassemia Major: An Update. Expert Rev Hematol 2016; 9: 401-408.
11. De Sanctis V, Soliman A, Yassin M. Iron Overload and Glucose Metabolism in Subjects with β-thalassemia Major: An Overview. Curr Diab Rep 2013; 4: 332-341.
12. Parkash O, Akram M. Hereditary Hemochromatosis. J Coll Physicians Surg Pak 2015; 25: 644-647.
13. Creighton Mitchell T, McClain DA. Diabetes and hemochromatosis. Curr Diab Rep 2014; 14(5): 488.doi: 10.1007/s11892-014-0488-y.
14. Wiley F. Bronze Diabetes: The “Silent” Diabetes. Little-known condition signals hemochromatosis. Diabetes Self Manag 2016; 33: 32-35.
15. Gomber S, Dabas A, Bagmar S, Madhu SV. Glucose Homeostasis and Effect of Chelation on β Cell Function in Children With β-Thalassemia Major. J Pediatr Hematol Oncol 2018; 40: 56-59.
16. Barton JC, Acton RT. Diabetes in HFE Hemochromatosis. J Diabetes Res. 2017;9826930. doi: 10.1155/2017/9826930.
17. Armand P, Kim HT, Rhodes J, Sainvil MM, Cutler C, Ho VT, Koreth J, Alyea EP, Hearsey D, Neufeld EJ, Fleming MD, Steen H, Anderson D, Kwong RY, Soiffer RJ, Antin JH. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 852-860.
18. Porrini R, Campagna A, De Muro M, Trawinska M, Di Veroli A, Leonetti Crescenzi S, Petruckione L, Romano A, D’Addosio A, Rago A, Montanaro M, Andriani A, Niccola P, Montefusco E, Breccia M, Alimena G, Latagliata R, Tafuri A. Deferasirox in the Treatment of Iron Overload during Myeloproliferative Neoplasms (MPN). EHA Learning Center 2016; abs. release: 132899.
19. Nolte F, Höchsmann B, Giagoundidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol 2013; 92: 191–198.
20. Kohgo Y, Urabe A, Kiliņš Y, Agaoglu L, Warzocha K, Miyamura K, Lim LC, Glaser S, Wang C, Wiktor-Jedrzejczak W. Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias. Acta Haematol 2015; 134: 233-242.

Received: 12 March 2018
Accepted: 22 March 2018
Correspondence: Vincenzo De Sanctis, MD
Pediatric and Adolescent Outpatients Clinic
Quisisana Hospital
Ferrara, Italy
E-mail: vdesanctis@libero.it